Business
Stevanato Group Reports Revenue of €256.6 Million for the First Quarter of 2025
PIOMBINO DESE, Italy, May 08, 2025--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2025.
About this update from Stevanato Group S.p.a.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1418,"height":473,"url":"https://media.zenfs.com/en/business-wire.com/9632631a91439b2322955d0071815c07"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3Snk8WTHkeBa2J8Z5Te39A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/9632631a91439b2322955d0071815c07","width":960,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/A.2BoT_AbMAJN.wYLBR7_w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/9632631a91439b2322955d0071815c07","width":1200,"height":400}},"lazy":false},{"type":"text","content":"PIOMBINO DESE, Italy, May 08, 2025--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2025.","length":313,"tagName":"p"},{"type":"text","content":"First Quarter 2025 Highlights (comparisons to prior-year period)","length":64,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue for the first quarter of 2025 increased 9% to €256.6 million, and high-value solutions represented 43% of total revenue.","length":128,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Gross profit margin increased 80 basis points to 27.2%.","length":55,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Diluted earnings per share were €0.10, and adjusted diluted earnings per share were €0.10.","length":90,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Adjusted EBITDA margin increased 100 basis points to 22.4%.","length":59,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The Company is maintaining its fiscal 2025 revenue guidance of €1,160 million to €1,190 million, and is updating its guidance for adjusted EBITDA and adjusted diluted earnings per share to reflect the expected impact from tariffs. As a result, the Company now expects adjusted EBITDA in the range of €288.5 million to €301.8 million, and adjusted diluted EPS in the range of €0.50 to €0.54.","length":390,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedL...